Tenderwize
Retour à la recherche

Open house drug discount agreements Safinamide, ATC N04BD03

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 552 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Safinamid, ATC N04BD03

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed volume or minimum revenue. The agreement may be superseded by other discount contracts, leading to early...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive discount agreements for the active substance Safinamide (ATC N04BD03) under § 130a Abs. 8 SGB V.
  • Contract duration: 24 months (01.05.2026 – 30.04.2028).
Afficher le résumé complet

This is an open-house model (not a standard procurement procedure) by AOK Bayern for non-exclusive discount agreements on the active substance Safinamide (ATC N04BD03). Any interested pharmaceutical company that meets the eligibility criteria can conclude an identical, non-negotiable discount agreement. The contract runs from 01.05.2026 to 30.04.2028, and new contracts can be concluded at any time until 03.03.2028. The agreement automatically terminates if a nationwide or region-specific discount contract for the same substance comes into effect. No estimated value is provided, and no award criteria apply as all qualified companies are accepted.

Risques

No guaranteed volume or minimum revenue. The agreement may be superseded by other discount contracts, leading to early...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company.

Administrative

  • Submit a signed declaration of reliability.
  • Submit signed contract and annex ("Festlegung der vertragsgegenständlichen Arzneimittel").

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria (open-house model). All eligible companies are accepted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house drug discount agreements Safinamide, ATC N04BD03

Non-exclusive discount agreements for Safinamide (ATC N04BD03) with AOK Bayern. Open to all pharmaceutical companies meeting eligibility. Contract period: 01.05.2026 - 30.04.2028. Early termination possible with one month notice. Automatically void if other discount contracts for the same substance become effective.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria (open-house model). All eligible companies are accepted.

Détails de la procédure

Date de publication
15 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
179421-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30